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Abstract
Signal transduction, regulatory processes, and pharmaceutical responses are highly dependent 
upon ligand residence times. Gaining insight into how physical factors influence residence times, 
or koff, should enhance our ability to manipulate biological interactions. We report experiments 
that yield structural insight into koff for a series of eight 2,4-diaminopyrimidine inhibitors of 
dihydrofolate reductase that vary by six orders of magnitude in binding affinity. NMR relaxation 
dispersion experiments revealed a common set of residues near the binding site that undergo a 
concerted, millisecond-timescale switching event to a previously unidentified conformation. The 
rate of switching from ground to excited conformations correlates exponentially with Ki and koff, 
suggesting that protein dynamics serves as a mechanical initiator of ligand dissociation within this 
series and potentially for other macromolecule-ligand systems. Although kconf,forward is faster than 
koff, use of the ligand series allowed for connections to be drawn between kinetic events on 
different timescales.
A long-sought goal in the biochemistry of receptor-ligand interactions is to gain an 
understanding of what molecular forces contribute to binding affinity and kinetics. A 
fundamental question is, how does dissociation occur once a ligand (e.g., peptide or small 
molecule) is bound to its receptor? This is an important question since ligand residence 
times control the strength of regulatory processes1–2. One model for dissociation is simple 
diffusion of ligand from the receptor. A more mechanistic reasoning would be that a specific 
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event physically disrupts the interaction between ligand and receptor, leading to ligand 
release or ejection. Indeed, myoglobin requires structural deformations to bind and release 
oxygen3–4; however, this can be viewed as a special case since ligand is completely buried 
from solvent. We postulate that protein structural fluctuations could be a more generally 
utilized mechanism for weakening intermolecular interactions and effectively ‘pushing’ or 
shearing a ligand away from its receptor. Experimental studies directed at this question 
should benefit structure-based drug design and protein (enzyme) engineering. From a 
biological perspective, because signal transduction is driven by countless cycles of ligand 
binding and release5, insight into mechanisms of ligand release could also make possible the 
drawing of fundamental connections between internal protein dynamics and cell signaling.
To probe the potential role of dynamics in small molecule ligand dissociation, we took a 
‘medicinal chemistry’ approach of observing how protein motions change in response to 
varying structural features within a ligand series. Enzymes are common pharmaceutical 
targets and exhibit considerable dynamics that are amenable to characterization by NMR 
relaxation dispersion6–11. Thus, to test our approach, we characterized relaxation dispersion 
in E. coli dihydrofolate reductase (DHFR) in complex with eight different antifolate 
inhibitors spanning an affinity range of six orders of magnitude. Three of these were 
reported previously: methotrexate (MTX), trimethoprim (TMP), and 1 [5-((4-
chlorophenyl)thio)quinazoline-2,4-diamine]12–13 (Fig 1a). This dataset comprises a 
‘dynamics structure-activity relationship’ (DSAR) series. In other words, this approach 
probes whether the dynamics of DHFR are sensitive to structural differences in small 
molecule ligands. As part of this series, five tetrahydroquinazoline inhibitors were designed 
to bind with reduced affinity for the purpose of loosening the ligands to allow detection of 
rare motions related to ligand dissociation. Although the location and rate of μs-ms 
conformational switching in DHFR depends on specific ligand structure, a cluster of 
residues around the active site dynamically samples the same excited state in all eight of the 
complexes. From the analysis of relaxation dispersion curves, the kinetics of conformational 
switching in DHFR were found to correlate with both Ki and koff, though the conformational 
switching was always faster than koff. These data implicate a common dynamic mechanism 
for dissociation of ligands within this series, and suggest that internal protein motion may be 
a critical event for ligand dissociation in general. The medicinal chemistry approach taken 
allows focused and methodical perturbations within the active site; this is in stark contrast to 
global systematic perturbations such as temperature variations or the addition of chemical 
denaturants. Recent studies have linked conformational dynamics with catalytic timescales 
through coincidental values of rate constants 8,14. We show here – through use of a ligand 
series – that linkages can also be made between events on different timescales.
RESULTS
Antifolate series spans a large range of Ki and koff
From a previous study of the dynamics of DHFR in the presence of the high affinity (Ki ≤ 1 
nM) inhibitors MTX and TMP (Fig. 1a and Supplementary Fig. 1a–b), both inhibitors 
elicited the same pattern of slow motion in the enzyme12. We wondered whether that same 
pattern of dynamics would be observed for any inhibitor bound to the same site, regardless 
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of binding affinity or chemical structure. To address this question, a series of substrate-
competitive DHFR inhibitors, or antifolates, with Ki values greater than 1 nM was designed. 
This series is comprised of five tetrahydroquinazoline-2,4-diamine compounds (compounds 
2–6, Fig. 1b). Compounds 2, 3, 4, and 6 are constitutional isomers and differ only in the 
placement of the methyl substituent on the tetrahydroquinazoline (THQ) ring. These 
compounds were prepared as racemic mixtures of methyl R and S forms. Inhibitor 5 lacks 
the methyl substituent and thus serves as a non-enantiomeric reference. Compounds 3 and 4 
were previously identified as competitive inhibitors of DHFR from a high-throughput screen 
of 50,000 small molecules15. We postulated that 2, 5, and 6 would have Ki values similar to 
those published for 3 and 4 on the basis of structural similarity. As with the three previously 
studied high affinity inhibitors (MTX, TMP, and 1)12–13, binding, structural, and dynamics 
properties were characterized for the THQ inhibitors in the presence of cofactor NADPH.
Ki values for the THQ inhibitors (Ki,app in the case of racemic mixtures) were determined to 
confirm previous measurements15 and to establish values for the new compounds. The Ki 
values cover a range of two orders of magnitude (0.3 – 43 μM, see Table 1), and the THQ 
compounds, as well as 1, are named according to increasing Ki/Ki,app (i.e., 1 is the strongest 
inhibitor and 6 the weakest). Overall, the methyl substituent contributes positively to the 
binding affinity, as evidenced by 2–4 having significantly lower Ki,app than the Ki of 5. 
Surprisingly, the methyl group at the C5 position of 6 increases Ki,app by > 40-fold relative 
to 2–4. The low apparent affinity of 6 relative to 2–5 is discussed in Supplementary 
Methods. From this analysis of binding affinities, it is clear that DHFR is very sensitive to 
minor changes in bound ligand structure.
Next, the binding kinetics for the THQ series were determined. The off-rate (koff or koff,app) 
for each inhibitor was determined using competitive stopped-flow fluorescence 
measurements. The series was found to span two orders of magnitude in koff (0.2 – 20 s−1), 
similar to the trend in Ki (Table 1). In fact, the relationship between Ki and koff for these five 
antifolates is linear (Fig. 1c). The calculated kinetic on-rates for the THQ series are similar, 
in the range of 3 × 105 – 3 × 106 M−1s−1. In the context of the entire antifolate series (MTX, 
TMP, and 1–6), Ki spans a range of 106, koff spans 105, and kon spans 102. It therefore 
follows that, given Ki = koff/kon and kon has relatively little variation within the ligand series, 
binding affinity is determined largely by the rate of dissociation. Within the THQ series 
alone, the effect of koff on Ki is larger than kon, but koff is less dominant than when 
considering all eight antifolates.
To test whether the precise R or S methyl orientation had a significant influence on binding, 
we separated the enantiomeric forms of 3. We found that the two forms had koff values that 
differed by 1.6-fold, suggesting that R and S forms are essentially indistinguishable. This is 
further supported by the observation that HSQC spectra of the complex formed from the 
racemic mixture did not show peak doublings, which would be expected if 3R and 3S have 
differential influence on DHFR.
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Structural differences induced by the series are minimal
In characterizing the protein dynamics of a series of receptor-small molecule complexes, any 
structural differences must be considered, as large changes can underlie differences in 
observed dynamics. Large structural changes in DHFR were not expected, given the 
chemical similarity of the antifolates. High-resolution crystal structures were determined for 
E:NADPH:3, E:NADPH:4, and E:NADPH:5 in the P212121 space group (Fig. 2a and 
Supplementary Table 1). As expected, the overall structures are highly similar (largest 
backbone rmsd = 0.28 Å). The THQs bind in the folate binding pocket of DHFR, which 
forms a small crevice in the structure but is not closed off by the protein. We note that for 
the C6 methyl substituent of 3, electron density was apparent for only one enantiomer (R) 
(Supplementary Fig. 2a), which could be due to a number of factors, such as the subtle 
difference in off-rate (see above). It is also possible that the S form also crystallized and that 
R and S methyls are not resolvable given the resolution of this structure (2.09 Å), although 
we view this as unlikely. In contrast to E:NADPH:3, electron density for both R and S forms 
in the E:NADPH:4 structure were observed (Supplementary Fig. 2b). The slight differences 
in sugar puckers resulted in R and S methyl groups occupying the same space 
(Supplementary Fig. 2b). Regardless of the enantiomers present, the THQs overlay very 
closely with one another (Fig. 2a). In addition, the 2,4-diamine moieties of 3–5 overlay 
closely to that of MTX16–17, although the orientation is slightly tilted such that the saturated 
ring of the THQs shift ~1 Å towards the side chain of Phe31.
Subtle differences in the protein structure are observable in helix C above the antifolate 
binding site, in the loop that follows helix C, and at N23 in the Met20 loop. The orientation 
of helix C is particularly noteworthy, since plasticity of this helix appears to accommodate 
the binding of various ligands, as noted previously17. Tilting of the C-terminus of this helix 
away from the antifolate binding site was identified previously in the presence of 1 (and 
NADPH), which contains a bulky and flexible side chain13. When overlaying the current 
three structures (PDB IDs 3R33, 3QYL, and 3QYO) with previously determined inhibitor 
complexes E:NADPH:1 and E:NADPH:MTX (PDB IDs 3KFY and 1RX3), we find that the 
C-terminus of helix C is tilted away from the antifolate binding site in E:NADPH:3 and 
E:NADPH:1, whereas it is positioned closer to the antifolate binding site in E:NADPH:4 
and E:NADPH:5 (Fig. 2b). In the case of 3, the R methyl substituent at C6 is oriented 
towards the helix, forcing it away. By contrast, the methyl substituents at C7 in 4 are 
directed away from the helix, and there is no methyl in 5, allowing the C helix to move 
closer to these antifolates. The position of helix C in E:NADPH:MTX is intermediate 
between the shifted extremes of complexes 1/3 and 4/5 (Fig. 2b). While this helix 
orientation appears to be sensitive to bound antifolate structure, it does not correlate with Ki 
of the bound antifolate.
Unlike the structure of E:NADPH:1 determined previously13, the ternary complexes with 3, 
4, and 5 show strong electron density within the Met20 loop. The loop was modeled in the 
closed conformation, similar to that observed in the presence of MTX. The closed Met20 
loop conformation is also observed in solution for all five ternary complexes based on NMR 
chemical shift perturbations (CSPs) (Supplementary Fig. 2c). In all three crystal structures, 
strong electron density is observed for NADPH and bound antifolates (Fig. 2a and 
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Supplementary Fig. 2a–b). Ligand orientations were also confirmed to be identical in 
solution as assessed by CSPs (Supplementary Fig. 2d–e). Based on these and the above 
considerations, no significant differences in structure are observed among these five ternary 
complexes. A straightforward comparison of differential dynamics of complexes in this 
series is therefore possible.
Slow timescale dynamics structure-activity relationships
By registering changes in DHFR’s dynamics as inhibitor structure is varied, dynamics 
structure-activity relationships (DSAR) are obtained. For each of the five THQ complexes, 
μs-ms motion was detected by 15N Carr-Purcell-Meiboom-Gill (CPMG)-relaxation 
dispersion experiments18. The dynamics of DHFR on this timescale have been shown to 
occur as a sequence of loop motions important to catalytic function when bound to 
endogenous ligands8. In addition, interesting differences in slow motions are observed in 
binary complexes that are off the enzyme’s catalytic cycle (E:folate, E:dihydrofolate) 
compared to the ‘on-cycle’ binary product complex (E:tetrahydrofolate), confirming the 
enzyme’s innate sensitivity to different ligands19. Relaxation dispersion experiments allow 
for the determination of the transverse relaxation rate due to conformational exchange (Rex), 
which is a component of the overall rate of transverse relaxation (R2):
(1)
where R2o is the intrinsic transverse relaxation rate in the absence of exchange. Assuming a 
two-state exchange process, these experiments provide kinetic, thermodynamic, and 
structural information about the transition: Rex depends on the exchange rate constant (kex), 
the populations of ground state A and excited state B (pA and pB), and the difference in 
chemical shift between states A and B (Δω)20.
In contrast to the high similarity of μs-ms dynamics that result from MTX or TMP binding12 
(Supplementary Fig. 1a–b), the THQ inhibitors elicit a more heterogeneous distribution of 
sites showing Rex (Fig. 3 and Supplementary Fig. 3). However, among the eight complexes 
there are twelve consensus residues with slow motions (discussed below). Thus, the pattern 
of slow motion elicited by MTX and TMP is not restricted to high-affinity antifolates. In 
addition to the consensus ‘antifolate sites’, new motions are detected near the hinge region 
(residues 38 and 88) and in α-helices C and F as Ki increases. Although within the THQ 
series there appears to be no significant correlation between Ki and number of sites with Rex, 
as a whole this series has a greater amount of Rex compared with MTX and TMP. None of 
the motions in the series are suspected to be the result of association-dissociation cycle 
effects, as koff values are slow (Table 1) and complexes are saturated to ≥ 99.5%.
As highlighted in previous NMR studies of the enzyme, the chemical shifts of a group of 
~20 residues report directly on the conformation of the Met20 loop21. These ‘marker’ 
residues have distinct chemical shifts when the loop samples either the closed or occluded 
conformation. In the E:NADPH:6 complex, significant Rex is observed at Met20 loop 
switching markers, suggestive of a functional conformational switch from closed to 
occluded21. However, only five sites show a correlation between Δω fitted from relaxation 
dispersion and Δδ for closed-to-occluded motion of the loop (Supplementary Fig. 4i; 
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residues 12, 115, 118, 120, and 149). While the loop appears to be mobile, its motion is not 
as clear and coherent as observed previously in the presence of 1 (13 sites in the 
correlation)13. We believe this Met20 loop motion to be the result of steric clash between 
nicotinamide of NADPH and the C5 methyl group of 6 within the active site (see 
Supplementary Methods). Residues within the F–G and G–H loops are the best 15N markers 
of Met20 loop switching (e.g., 115, 116, 118, 119, 120, 121, 122, 149, and 150), not those 
within the Met20 loop itself. It should be noted that the 15N Met20 loop marker residues 
within the F-G and G-H loops are not generally observed to undergo μs-ms motion in the 
presence of compounds 2–5 of the series (Supplementary Tables 2 and 4) and that even the 
best examples of closed complexes (with bound MTX or TMP) exhibit exchange broadening 
at some of the marker residues. In further support of E:NADPH:6 being different from the 
other complexes regarding its Met20 loop mobility, G121 is severely broadened in the 
presence of 6 but not for the remaining compounds of the series.
Rate of conformational switching correlates with Ki and koff
Residue-grouped fitting of relaxation dispersion data can indicate which sites move together 
in a single, concerted exchange process22. Residues that are included in a group fit are 
forced to share single kex and pA values, whereas they retain their individual Δω values. To 
probe whether the observed Rex values reflect concerted conformational exchange processes, 
group fits were carried out for all of the ternary THQ complexes. For 3, 5, and 6, group 
fitted kex values were found to range from 1000–1500 s−1, which are greater than those for 
the higher affinity antifolates (400–800 s−1), and pB remained fixed at approximately 2% 
(Table 1). It follows that the forward rate of conformational exchange (kconf,forward) ranges 
from 20–35 s−1 for these three complexes. Initial plots of kconf,forward versus Ki suggested a 
correlation for these three protein-inhibitor complexes. To further test this correlation, 
kconf,forward and Ki for MTX, TMP, and 1 were added to the plot (Tables 1 and 2)12–13,23. 
For these six complexes, covering six orders of magnitude in binding affinity, we find that 
kconf,forward correlates exponentially with Ki (Fig. 4a). As binding affinity decreases (larger 
Ki), kconf,forward increases (Table 1). Unfortunately, single-group fitting for complexes 2 and 
4 did not converge and thus are not further supportive of this trend, although an alternative 
fit for 4 was obtained (see Methods). Based on the exponential relationship between 
kconf,forward and Ki and the linear correlation between Ki and koff (Fig. 1c), kconf,forward vs. 
koff was plotted and found to correlate exponentially (Fig. 4b). We note that kconf,forward is 
always greater than koff by at least a factor of two for each complex, providing further 
evidence against kex resulting from association-dissociation cycles. This correlation of 
kconf,forward and koff, with kconf,forward > koff, is highly suggestive of a mechanistic role for 
the ground-to-excited state conformational change in ligand release. In Figure 4b, because 
koff for TMP and 1 are too slow for detection via the assay employed, they were calculated 
from Ki and their approximate kon value for the series. The koff value for MTX was taken 
from the literature24. The best fitted kconf,forward for 4 has been included in Figure 4b, even 
though group fitting was more challenging in this case; its position off the main correlation 
line suggests that additional factors may contribute to release for a particular ligand, even if 
it is part of a structurally constrained series. Nevertheless, the fact that the remaining ligands 
fall on the line suggests that the millisecond structural fluctuations potentiate dissociation 
over the entire ligand series, including MTX and TMP.
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Antifolate complexes sample the same excited state
Relaxation dispersion experiments can also provide structural information about the excited 
state. As mentioned previously, from data on the eight drug/inhibitor complexes, there are 
~twelve consensus residues undergoing μs-ms motion (Fig. 5a). We define a residue as a 
consensus site if slow motion is detected at that position (when assignable) in (a) ≥ 2/3 of 
the eight complexes (residues 8–11, 14, 29, 31, 111–113), or (b) ≥ ½ of the complexes when 
Rex is significant in the other half but lies just below our stringent requirement of 2 s−1 
(residues 7 and 30). A number of these sites were initially identified from the least dynamic 
complexes, those with MTX or TMP bound12. The dynamic change in chemical shift (Δω) 
at these consensus sites fitted from relaxation dispersions for each complex were analyzed. 
For each individual residue, the fitted Δω parameter clusters around the same value, despite 
changes in chemical structure and binding affinity for the different inhibitors (Fig. 5b). This 
clustering of Δω values indicates that the same excited state is being sampled by the 
consensus residues in each of the eight antifolate complexes. This pattern of Δω values does 
not correlate with Δω fitted from previous studies of DHFR bound to physiological, folate-
derived ligands (Supplementary Fig. 4j)8 and hence is unique to the antifolates studied here. 
In addition, because poor correlations between Δω fitted from the dispersion data and Δδ 
from chemical shift changes (E:NADPH – E:NADPH:antifolate) were observed for the 
consensus sites (Supplementary Fig. 4a–h), the antifolates appear to be bound in the excited 
state. We propose that these residues sampling a novel excited state mediate dissociation of 
antifolate ligand. This state is sampled at somewhat different rates, but the concerted motion 
of the consensus residues is conserved across these antifolate complexes.
We note that while these complexes share this common dynamic sampling, differences in 
slow motions remain among the complexes12–13 (Fig. 3, Supplementary Table 2). Thus, this 
shared motion appears to be able to exist in the context of additional motions (or lack 
thereof) in other regions of the enzyme.
DISCUSSION
Binding and dissociation are the two fundamental processes that determine a ligand’s 
affinity for its receptor. Mechanistic insight into these processes is therefore expected to 
facilitate rationale design of drugs and macromolecules with desired ligand binding 
properties. To evaluate whether conformational dynamics should be considered as relevant 
to ligand dissociation, we monitored the dynamics of a classic drug target, DHFR, that is 
known to undergo extensive motions on the μs-ms timescale. The wide range of affinities of 
the eight inhibitor complexes studied elicited a variety of dynamic behavior in the enzyme, 
and therefore this constitutes a dynamics structure-activity relationship (DSAR). This is 
distinct from, yet complementary to, flexibility-activity relationships (FAR), which focuses 
on dynamics of the bound ligand as shown previously for peptide ligands of Pin125. Our 
results underscore the benefits of using a series of ligands to extract a kinetic relationship 
between internal motion and dissociation. A similar benefit from use of a ligand series was 
demonstrated recently for correlating ps-ns dynamics with conformational entropy in the 
case of calmodulin26.
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Here we show that, for a series of homologous antifolates binding to DHFR, binding affinity 
(Ki) is determined largely by koff. We also demonstrate from CPMG relaxation dispersion 
measurements that the rate of millisecond-timescale internal motions in the enzyme 
(kconf,forward) is related to both binding affinity and koff for the series. Specifically, the 
correlation of kconf,forward to koff provides evidence that internal protein motion is a 
mechanical initiator of ligand dissociation. Analysis of chemical shifts suggests that DHFR 
samples an identical excited state in solution regardless of which particular antifolate is 
bound, and that this state is novel because it differs from the excited states observed in the 
absence of ligand and in physiological complexes (Supplementary Fig. 4j). It is also worth 
noting that the THQ complexes undergo switching ~3 times faster than the physiological 
complexes. Because ligand is bound in the excited state and the rates of internal motion 
correlate with koff, we propose that this excited state is en route to dissociation of inhibitor 
and kconf,forward provides an upper limit to koff.
In previous work, connections between internal motions and protein activity have been 
drawn when an internal switching rate precisely matches a macroscopic rate constant8,14. 
We show here, through the use of a homologous ligand series, that such matching is not 
required to mechanistically connect two functional events. Ligand dissociation is 
fundamental in macromolecular interactions, and insights into what stimulates dissociation 
have potentially broad implications for manipulating biological systems. The main insight 
revealed here is that dissociation can be driven by defined protein internal motion, 
presumably at the interface, rather than by a fully stochastic process. This inference of 
motions driving dissociation would seem to be expected for a buried binding site in which a 
‘lid’ must open for release; however, in this particular case, the ligand binding site is 
exposed, and yet dissociation appears to not be stochastic.
At what point during the conformational sampling does release actually occur? The simplest 
model consistent with our data is the following conformational gating model:
(2)
Upon transitioning to the excited state (state B), ligand remains initially bound but is subject 
to release while the gate is open, with rate constant koff,B. In this model, release might 
depend on sub-millisecond motions that essentially kick out the ligand or break non-
covalent interactions through shearing motions. Release from the open gate could also occur 
in a stochastic manner based on the overall strength of interactions (see below). Eqn. (2) is 
formally equivalent to the Linderstrom-Lang model for amide H/D exchange27. Hence, the 
overall rate constant for dissociation can be expressed28 as koff = (kconf,fwd·koff,B)/(kconf,fwd 
+ kconf,rev + koff,B), which can be rearranged to
(3)
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in which Kconf = kconf,fwd/kconf,rev and koff is the bulk dissociation rate constant. Use of eqn. 
(3) yields values of koff,B ~25–100 times that of koff, indicating significantly faster 
dissociation from the excited state (Supplementary Table 5) compared to the rate obtained 
when assuming simple dissociation from the ground state. We note that this gating model 
excludes ligand rebinding and hence is consistent with kinetic decay experiments. Rebinding 
may occur via different structures/mechanisms since the antifolate excited state is not 
observed in the holoenzyme (DHFR:NADPH, see Figure S4j).
What is somewhat surprising from the correlation of kconf,forward to Ki and koff is that the 
relationship is log-linear. It follows that DHFR is not productive at releasing inhibitors each 
time it reaches the excited state, as kconf,forward is always greater than koff. Thus, the enzyme 
appears to be more efficient at release as the rate of internal motion increases. Within the 
gating model, this may be explained by a loss of substituents. Adding substituents to the ring 
beyond the 2,4-diaminopyrimidine scaffold (e.g., methyls in THQ series, methoxy groups in 
TMP, etc.) could have a dual effect on the steps shown in eqn. (2): (i) these groups could 
serve to slow switching, as observed, due to stabilization of both ground and excited states, 
and (ii) by providing additional contacts to protein, these substituents would reduce the 
probability of stochastic release from the excited state, as observed (Fig. 4b, Table 1). 
Overall, the lack of a true linear relationship indicates an additional process (beyond the 
conformational change detected here) is associated with the final release of ligand.
An important caveat is that any ligand bearing resemblance to the series (or that binds to the 
same active site) should not necessarily obey the correlation in Figure 4b. Indeed, 2 and 4 do 
not (see Supplementary Results). It is reasonable to expect that numerous mechanisms for 
ligand release could compete with one another, and some ligands may trigger specific 
mechanisms over others due to their chemical structure. We have been fortunate here in 
using a panel of ligands that share a common mechanism that is distinct from release of 
folate-derived ligands. It will be interesting to see whether other ligand series against 
different proteins show similarity in behavior as was observed here.
Gaining an understanding of the molecular basis of koff has implications for structure-based 
drug design. If protein dynamics are found to correlate with koff in other systems, this type 
of analysis may be useful in optimizing ligand residence times to meet the desired 
pharmaceutical modulation of disease states. The DSAR methodology provides more than 
just a correlation between the rate of internal motions and koff – it also potentially provides 
structural information on residues sampling multiple conformations and even what the 
structure of the excited state(s) may be29–30. This combined information would be useful in 
directing medicinal chemistry efforts toward modulating the stability of excited states that 
promote efficient ejection of inhibitors.
METHODS
Synthesis of (6-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine) (compound 3)
Compound 3 was prepared by a one-step condensation reaction, similar to that described 
previously31. Briefly, dicyandiamide (10.19 g, 0.12 moles) and 4-methylcyclohexanone 
(11.33 g, 0.10 moles) were combined in a round bottom flask fitted with a Dean-Stark trap 
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and a condenser. The reaction was heated in an oil bath at 180 °C for three hours. Boiling 
water was added to the reaction as it was transferred to a separatory funnel for extraction. 
The desired compound was extracted from the aqueous layer with hot chloroform. The 
chloroform washes were dried over anhydrous magnesium sulfate before solvent was 
removed via rotary evaporation. A golden yellow liquid with white precipitate remained. 
Additional white solid was precipitated via addition of hexanes to the yellow liquid. The 
solid was isolated via filtration.
Synthetic procedures for 2 and 4–6 follow from that described above (Supplementary 
Methods). Spectroscopic data for all five compounds is summarized in Supplementary 
Methods. The enantiomers of 3 were separated on a Thar Investigator analytical/semi-
preparative SFC. Purification was carried out using 20% isopropyl alcohol (0.1% 
diethylamine) in CO2 with a CHIRALPAK IC column from Chiral Technologies.
Ki determination
As described previously, biochemical competition assays using a 96-well plate reader were 
used to determine the inhibition constant (Ki) for 2–613,15. The decrease in absorbance at 
340 nm was monitored over time in a 2D titration of inhibitor and substrate.
Protein expression and purification
Isotopically labeled wild-type E. coli DHFR was over-expressed and purified as described 
previously12. Purified apo-DHFR was flash frozen, lyophilized, and stored in a desiccator at 
4 °C until use.
NMR Spectroscopy
For ternary inhibitor complexes, samples contained 1 mM DHFR in NMR buffer (70 mM 
HEPES, 20 mM KCl, 1 mM EDTA, 1 mM DTT [pH 7.6]), 15 mM NADPH, 2.5–10 mM 
antifolate (E:NADPH:2 – 10 mM; E:NADPH:3 – 2.5 mM, E:NADPH:4 – 8–10 mM; 
E:NADPH:5 – 10 mM; E:NADPH:6 – 10 mM), 10 mM glucose-6-phosphate, 10 U 
glucose-6-phosphate dehydrogenase, and 10% D2O for spectrometer locking purposes. All 
samples were protected from light and air exposure by containment in amber NMR tubes 
flame-sealed under argon. Stock solutions of 2–6 were prepared in 10% D2O/H2O and 
PULCON was used to determined the concentration of each stock, relative to either valine or 
trimethoprim standards32. NMR experiments were performed as described previously, using 
both room temperature (500, 600, and 700 MHz) and cryogenic (500 and 700 MHz) 
probes12–13. NMRPipe was used to process NMR data, and data visualization was 
accomplished with the combination of NMRDraw and NMRView33–34. Refer to 
Supplementary Methods for further experimental details on assignment and relaxation 
experiments.
CPMG relaxation dispersion—15N CPMG relaxation dispersion experiments were 
conducted on highly deuterated (>80%) DHFR for the E:NADPH:2 and 4–6 complexes 
while protonated DHFR was used for E:NADPH:3. Complexes with bound 2–4 were 
examined using a TROSY relaxation dispersion experiment at 700 MHz with a room 
temperature probe. Data collection at 700 MHz for complexes with bound 5–6 utilized a 
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cold probe and the regular non-TROSY experiment. Collection and analysis of the data was 
completed as described previously12–13.
For group fits, all residues in a particular complex exhibiting significant μs-ms motion 
(excluding the C-terminal residues, see Supplementary Table 3) were grouped together, 
following the method of Mulder et al22. Single kex and pA values were fit for a group, 
whereas Δω values were fit in a residue-specific manner. Residues found to have a 
significantly improved local fit relative to the group fit (i.e., having a χ2group/χ2local ratio of 
> 2) are reported with Δω values from the local fit instead of the group fit. Although it is 
possible that multiple groups with slightly different exchange parameters exist for individual 
complexes, because such differences are small in most complexes, they cannot be easily 
resolved and the simplest case of a single group was used. In the case of E:NADPH:2 and 
E:NADPH:4, single-group fits of all residues together would not converge. Upon removal of 
four residues with increased local kex values (37, 50, 54, and 58), group fitting for 
E:NADPH:4 converged and the residues appeared to fit together based on χ2 ratios. This 
same approach for E:NADPH:2 resulted in convergence (40, 44, 48, 50, 54, 57, 98, 115, and 
119 removed); however, the residues did not group well together based on χ2 ratios. Group 
fits for complexes with bound 2 and 4 are reported, but it should be noted that the fits were 
not conducted in the same fashion as for the rest of the series. One interesting point to 
mention is that E:NADPH:2 and E:NADPH:4 resulted in similar group fitting for both the 
‘slow’ and ‘fast’ moving sets of residues. We speculate that the similar placement of the 
methyl substituent in these two inhibitors may underlie why they appear to cause faster 
switching motions in DHFR. Also, for inhibitors 2 and 4, the possibility that both R and S 
enantiomers bind could also result in different switching than for the remainder of the series, 
although this appears not to be the case for 6.
The sign of Δω was determined from peak positions in HSQC and HMQC spectra35. Sign 
determination for Δω was completed on six of the eight ternary complexes (E:NADPH:2 and 
E:NADPH:4 excluded). Given the strong pattern of Δω sign observed for the antifolate 
consensus residues (Fig. 4d), the signs for the complexes with 2 and 4 were assumed to 
agree with the pattern. Additionally, the sign of Δω determined for the three other THQ 
compounds (3, 5–6) should be representative of 2 and 4. Fitted parameters and the sign of 
Δω are summarized for each complex in Supplementary Results.
Protein crystallization and structure determination
Crystals of E:NADPH:3, E:NADPH:4, and E:NADPH:5 were grown using similar 
conditions as described previously13,17,36. See Supplementary Methods and Results for 
details of crystallization, data collection, and structure refinement.
Determination of koff
A fluorescence competitive binding assay, as described previously, was used to determine 
koff for 2–6 from the E:NADPH holoenzyme13,37. Refer to Supplementary Methods for a 
detailed methods description.
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Refer to Web version on PubMed Central for supplementary material.
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The series of reduced-affinity and previously characterized antifolates. (a) Chemical 
structures of the previously characterized antifolates – methotrexate (MTX), trimethoprim 
(TMP), and 1. (b) Chemical structures of the reduced-affinity antifolates 2–6. (c) The 
relationship between koff and Ki for the series of reduced-affinity antifolates (R = 0.99).
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High resolution crystal structures for the series. (a) Overlay of the crystal structures for 
E:NADPH:3 (blue), ENADPH:4 (teal), and E:NADPH:5 (maroon). NADPH is shown in 
cyan and bound antifolate in the colors designated per complex. (b) Expansion of the C-
helix, now overlaying five inhibitor-bound complexes (E:NADPH:1 in dark grey and 
E:NADPH:MTX in light grey). PDB IDs are listed parenthetically. (c) Differential 
puckering of the saturated ring in the bound inhibitors, colored as in (a).
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Slow timescale dynamics for the reduced-affinity inhibitor series. Sites along the backbone 
with detectable μs-ms motion are highlighted in colored spheres for each complex, ordered 
from left to right by increasing Ki value. The number of residues with significant Rex is 
given parenthetically.
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Internal motions vary with Ki and koff. (a) The forward rate of motion (kconf,forward) fit from 
relaxation dispersion data for each complex varies exponentially with the Ki value for the 
bound inhibitor (R = 0.97). The open circle represents the best fit for E:NADPH:4. (b) An 
exponential correlation is also seen between kconf,forward and koff (R = 0.97). Data points in 
red have predicted koff values, as described in the text. koff for TMP and 1 were calculated 
based on estimated values for kon. For 1, the average kon for the THQ series was used. For 
TMP, because of its greater similarity to MTX, kon was taken to be intermediate between 
MTX and the average value for the THQ series. The data point for E:NADPH:4 (unfilled 
circle) does not fall along this exponential correlation, suggesting that this correlation may 
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not always be predictive. The dashed curve represents what would be expected if the 
correlation were linear. Error bars represent standard deviations (originating from Monte 
Carlo simulations in the case of kconf,forward).
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Antifolate consensus sites sample a structurally similar excited state. (a) The twelve 
antifolate consensus sites are highlighted in yellow colored spheres. (b) Dynamic Δω values 
fitted from relaxation dispersion for these twelve sites cluster for each residue. The eight 
complexes are colored by the bound inhibitor, as indicated in the legend. Averages were 
calculated only from residues that have the dominant sign. No bar is shown if that residue 
did not exhibit significant slow motion while bound to a particular inhibitor. Error bars 
result from standard deviations derived from Monte Carlo simulations.
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